Invasive fungal infections carry a 30–90% mortality in immunocompromised patients. Azole exposure varies up to 10-fold between patients, making TDM not just useful, but essential for survival.
The Clinical Problem
Antifungal Dosing
Cannot Be Fixed
Systemic antifungal therapy is uniquely challenging. Azoles exhibit highly variable pharmacokinetics governed by CYP2C19 and CYP3A4 polymorphisms, food and formulation interactions, hepatic function, and a dense landscape of drug-drug interactions with immunosuppressants, antiretrovirals, and chemotherapy.
Subtherapeutic exposure drives treatment failure and selects for resistant Candida and Aspergillus species a growing global threat. Supratherapeutic levels cause hepatotoxicity, QTc prolongation, and voriconazole-associated neurotoxicity.
International guidelines from ESCMID, IDSA, and ECMM now recommend routine TDM for voriconazole, itraconazole, posaconazole, and isavuconazole in at risk populations. Our ClinPeak™ Antimycotic Assay delivers all eight analytes in a single, validated run.
ClinPeak™ — Full Panel
Antimycotic Assay — 8 Analytes
Comprehensive, simultaneous quantitation of all major systemic antifungal classes
azoles (1st, 2nd & 3rd generation), the active OH-itraconazole metabolite, and the pyrimidine analogue 5-fluorocytosine.
SERVICE CODE: AT-TDM-AMYC
🧪 Sample: Plasma / Serum | 📦 Volume: 500 µL | ⏱ TAT: 48–72 hrs | 🔬 Method: LC–MS/MS
Flexible Testing
ClinPeak™ Antimycotic Customized Assay
Not every patient needs all eight analytes. Select the specific antifungal agents relevant to your formulary, study protocol, or patient's treatment, with no compromise on assay quality or turnaround time.
CUSTOM ASSAY CODE: AT-TDM-AMYC-CUST
Precision Antifungal Therapy
Right Drug. Right Dose. Right Time.
Connect with our clinical team to discuss panel selection, send your first sample, or integrate ClinPeak™ into your institution's antifungal stewardship programme.
